A vaccine developed to tackle Streptococcus suis, an economically damaging disease endemic in the global pig population, has outperformed a leading commercially available vaccine in a challenge trial. The trial showed the vaccine candidate—developed by an international consortium including The Vaccine Group (TVG), the University of Plymouth and Moredun Scientific Limited—to be effective against a heterologous serotype of the disease.